Experience with sertaconazole in pregnant women with vulvo-vaginal candidiasis
https://doi.org/10.21518/2079-701X-2019-13-160-165
Abstract
Objective. To evaluate the clinical efficacy of sertaconazole in the treatment of acute vulvo-vaginal candidiasis (VVC) in pregnant women with caesarean section. Subject and methods. The study included 136 pregnant women. In the treatment, 1 candle of sertaconazole 300 mg once was used. Efficacy was evaluated after 7 and 28 days. Results. At 74.0% of pregnant women identified VVK. After treatment with sertaconazole, positive dynamics was observed in 91.9% of patients, in whom clinical manifestations of the disease disappeared by the third day. Culture testing revealed a normalization of the vaginal biotope at 97.1% of pregnant women. Our experience has shown the effectiveness of the drug, the absence of adverse events and good compliance due to the ease of use and rapid achievement of the therapeutic effect in pregnant women throughout pregnancy.
About the Authors
S. A. Gasparyan
Stavropol State Medical University
Russian Federation
Russian Federation
Susanna A. Gasparyan, Dr of Sci. (Med), Professor, Professor of the Department of Obstetrics and Gynecology of the Faculty of Additional Professional Education
310, Mira street, Stavropol, 355017
A. A. Khazhbiev
Nevinnomyssk City Hospital
Russian Federation
Russian Federation
Astemir A. Khazhbiev, postgraduate student of the Department of Obstetrics and Gynecology of the Faculty of Additional Professional Education of the Federal State Budgetary Educational Institution of Higher Education «Stavropol State Medical University» of the Ministry of Health of the Russian Federation; obstetrician-gynecologist, State Budgetary Healthcare Institution of the Stavropol Territory «Nevinnomyssk City Hospital»
310, Mira street, Stavropol, 355017, 5, Pavlova str., Nevinnomyssk, Stavropol Territory, 357112
V. V. Ryzhkov
Stavropol State Medical University
Russian Federation
Russian Federation
Valery V. Ryzhkov, Dr. of Sci. (Med), Professor, Head of the Department of Obstetrics and Gynecology of the Faculty of Additional Professional Education
310, Mira street, Stavropol, 355017
References
1. Prilepskaya V.N., Mirzabalayeva A.K., Kira E.F., Gomberg M.A., Apolikhina I.A., Bayramova G.R. Diagnostics and treatment of diseases accompanied by pathological excretions from the female genital tract. Federal clinical recommendations. М., 2013.] (In Russ.) Available at: https://docplayer.ru/26676497-Federalnye-klinicheskierekomendaciidiagnostika-i-lechenie-zabolevaniysoprovozhdayushchihsya-patologicheskimivydeleniyami-iz-polovyh-putey-zhenshchin.html.
2. Ryzhkov V.V., Khazhbiev A.A. Prevention of purulent-septic complications after cesarean section. Tavricheskiy mediko-biologicheskiy vestnik. 2017;20(2):190-197. (In Russ.) Available at: http://ma.cfuv.ru/docs/235847/%D0%A2.20%20%E2%84%962v2%202017.pdf.
3. Kokoeva D.N., Medzhidova M.K., Lomova N.A., Kan N.E., Tyutyunnik V.L. Prevention of premature birth in pregnant women with vaginal candidiasis. Meditsinskiy sovet = Medical Council. 2019;(7):52-57. (In Russ.) doi: 10.21518/2079-701X-2019-7-52-56.
4. Vulvovaginal candidosis. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):61-63. Available at: https://www.cdc.gov/mmwr/pdf/rr/rr5912.pdf.
5. Vosnesenskaya N.V., Charitonov V.M., Burganova R.F., Istomina N.S., Saakyan K.G. Sertaconazol (zalain) in the treatment of vaginal candida during pregnancy. Ul’yanovskiy mediko-biologicheskiy zhurnal = Ulyanovsk MedicoBiological Journal. 2013;(2):36-39. (In Russ.) Available at: https://www.old.ulsu.ru/images/stories/antipoviv/ulsubook/2013/2-2013.pdf.
6. Grigsby P.L., Novy M.J., Adams Waldorf K.M., Sadowsky D.W., Gravett M.G. Choriodecidual inflammation: a harbinger of the preterm labor syndrome. Reprod Sci. 2010;17(1):85-94. doi: 10.1177/1933719109348025.
7. Mucci M.J., Cuestas M.L., Cervetto M.M., Landaburu M.F., Mujica M.T. A prospective observational study of vulvovagintis in pregnant women in Argentina, with special reference to candidiasis. Mycoses. 2016;59(7):429-35. doi: 10.1111/myc.12490.
8. Tellapragada C., Eshwara V.K., Bhat P., Kamath A., Aletty S., Mukhopadhyay C. Screening of vulvovaginal infections during pregnancy in resource constrained settings: Implications on preterm delivery. J Infect Public Health. 2017;10(4):431-437. doi: 10.1016/j.jiph.2016.06.003.
9. Rotem R., Fishman B., Daniel S., Koren G., Lunenfeld E., Levy A. Risk of major congenital malformations following first-trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population-based retrospective cohort study. BJOG. 2018;125(12):15501556. doi: 10.1111/1471-0528.15293.
10. Veleminsky M. Jr, Pradna J., Veleminsky M. Sr, Tosner J. Relationship of amniotic-type placenta inflammation to PROM, PROM and risk of early onset neonatal sepsis. Neuro Endocrinol Lett. 2008;29(4):447-50. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18766145.
Review
For citations:
Gasparyan SA, Khazhbiev AA, Ryzhkov VV. Experience with sertaconazole in pregnant women with vulvo-vaginal candidiasis. Meditsinskiy sovet = Medical Council. 2019;(13):160-165. (In Russ.) https://doi.org/10.21518/2079-701X-2019-13-160-165
Views:
993
Email this article 